DRUGDOCS®’s Post

A patient-led organization has just made an incredible breakthrough by repurposing a drug for a rare and deadly bleeding condition! Recently, a large clinical trial revealed that pomalidomide, originally developed for multiple myeloma, has proven effective in treating a life-threatening bleeding disorder called HHT (Hereditary Hemorrhagic Telangiectasia). This drug not only reduced bleeding events but also improved patients’ quality of life. Cure HHT brought together physicians, researchers, and patients to push this repurposing opportunity forward, showing the true power of patient-led organizations. At Every Cure, we aim to work closely with patient organizations to identify the most promising opportunities from our platform and ensure the necessary trials are conducted to benefit as many patients as possible. Because no one understands a rare disease better than those living with it. #raredisease #drugdevelopment #drugrepurposing #clinicaltrial

🎯 Targeted Therapies for PsA and axSpA—Are You Ready? Join us on November 13, 2024, for a live webinar featuring Dr. Atul Deodhar, where we’ll dive into the latest clinical evidence and guidelines for treating Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA). Gain practical tools to improve your practice and patient outcomes! 🔗 https://ow.ly/Ho3t50TEyVn #OSPA2024 #Rheumatology #PsA #axSpA #VirtualLearning

“WITH RESPECT TO OPEN SURGICAL REVASCULARIZATION OF DISEASE LIMITED TO THE ABOVE-KNEE SEGMENT, THE PREFERRED BYPASS CONDUIT WAS THE GSV FOR TWO-THIRDS OF THE RESPONDENTS. FOR BELOW-KNEE SURGICAL REVASCULARIZATION, ALL REPORTED THE GSV AS THE PREFERRED OPTION." BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally. https://lnkd.in/ecXdFbnt https://lnkd.in/enGHNCz4 GSV AS POTENTIAL ARTERIAL BY-PASS SAVING IS POSSIBLE IN VARICOSE PATIENTS THANKS TO NON ABLATIVE SOLUTIONS VENOUS HEMODYNAMICS APPROPRIATE  KNOWLEDGE TO IMPROVE VARICOSE TREATMENT WHILE SPARING THE VALUABLE GSV as POTENTIAL ARTERIAL BY-PASS https://lnkd.in/eSYFNcQH LONG-TERM EFFICACY OF DIFFERENT PROCEDURES FOR TREATMENT OF VARICOSE VEINS A network meta-analysis Conclusion:CHIVA seemed to have superior clinical benefits on long-term efficacy for treating varicose veins. However, the conclusion still needs additional trials for supporting evidence. https://lnkd.in/eCAp-HCf

Successfully bringing innovative precision medicines to market requires comprehensive clinical strategies that move these therapies from discovery to clinic. Importantly, it also entails deliberate inclusion of key stakeholders along the entire value chain, from suppliers through to patients. Dive deeper into the considerations for precision medicine in rare disease trials in our therapeutic spotlight: https://ow.ly/67Yn50TFljF

Digital Therapeutics: The Future Of Personalized Medicine! In this article, our CEO Ayush Jain, discusses the transformative potential of digital therapeutics (DTx) in the healthcare industry. As chronic diseases become more prevalent, the need for tailored, evidence-based treatment solutions has never been greater. Discover how DTx is reshaping chronic disease management, enhancing patient engagement, and paving the way for a more holistic, patient-centered healthcare future. Read the full article here. 👇 https://lnkd.in/dyuQr2Qx #DigitalHealth #PersonalizedMedicine #ChronicDisease #Innovation #HealthcareTechnology Innovation & Tech Today American Medical Association American Hospital Association Digital Health Insights Becker's Healthcare FDA McKinsey & Company Pravin Uttarwar Manisha Khadge

FAQ: How Does Stretta Compare to Toupet Fundoplication? Ma et al. conducted a study to compare therapeutic efficacy of the two methods. Observing 226 patients undergoing TF or Stretta in a hospital setting, they compared baseline data, reflux symptoms, DeMeester scores, LES pressure and adverse events over a 1 year period. Compared with Toupet Fundoplication, minimally invasive Stretta therapy can significantly improve the esophageal pH and pressure in GERD patients, without increasing the risk of poor prognosis. #reflux #GERD #fundoplication https://lnkd.in/geGwEB6u

Did you know that chronic diseases account for a whopping 84% of deaths globally? That's a staggering number. Digital therapeutics (DTx) are transforming the way we treat chronic conditions. These aren't just apps; they're evidence-based treatments delivered right to your smartphone for personalized care, improved engagement, and better outcomes for chronic conditions like diabetes, hypertension, and mental health. Read the article to learn more! Innovation & Tech Today American Medical Association American Hospital Association Digital Health Insights Becker's Healthcare BioSpace McKinsey & Company FDA Manisha Khadge Pravin Uttarwar #digitaltherapeutics #personalizedmedicine #healthcare #wellness #healthtech #futureofhealthcare

We are excited to present our experience with the use of Anifrolumab in SLE patients. The aim of this study was to examine the patient perspective and present our clinical experience of the treatment. This was a cross-sectional, non-interventional qualitative interview study employing a hybrid approach, combining primary data from one-on-one qualitative patient interviews and secondary data from a collection of patient data from electronic medical records (EMR). Patients reported overall symptom improvement with Anifrolumab, despite ongoing disease impact. EMR data demonstrated reduced disease activity and decreased corticosteroid usage post-treatment. This study enhances our understanding of the patient perspective of Anifrolumab treatment as well as providing us with real world data on the efficacy of the treatment. This research is published in Lupus and can be accessed here: https://lnkd.in/dTGYxUKg Anne Troldborg, Daniel Eek, Lauren Remkus, Bent Deleuran  #RheumAarhus #Lupus #SLEtreatment #patientperspective

Delve into the intricacies of Paroxysmal Nocturnal Hemoglobinuria (PNH) through our latest published article. We unravel a rare complication, Popliteal Artery Thrombosis, shedding light on its clinical manifestations, diagnostic challenges, and therapeutic interventions. This insightful case report offers valuable insights for clinicians and researchers alike, aiming to enhance our understanding and management of PNH-related complications. #PNH #Thrombosis #MedicalResearch

𝐏𝐮𝐫𝐞𝐓𝐞𝐜𝐡 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐈𝐏𝐅 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐋𝐘𝐓-𝟏𝟎𝟎 𝐚𝐭 𝐂𝐇𝐄𝐒𝐓 𝟐𝟎𝟐𝟒 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) PureTech Health, a clinical-stage biotherapeutics company, recently presented two oral presentations and a poster at the CHEST 2024 Annual Meeting in Boston, focusing on LYT-100 (deupirfenidone) for idiopathic pulmonary fibrosis (IPF). The presentations highlighted significant gaps in disease management and quality of life for IPF patients. A survey of 90 participants revealed that common symptoms such as shortness of breath, fatigue, and cough significantly interfere with daily activities, underscoring the need for better treatments. Additionally, the company shared insights into its ongoing Phase 2b ELEVATE IPF trial, which is evaluating the efficacy and safety of LYT-100. By utilizing a Bayesian approach, the trial enhances statistical power by incorporating historical placebo data, reducing the number of patients treated with placebo. The results from this trial are expected by the end of 2024 and could serve as the foundation for advancing LYT-100 into Phase 3 and eventual global registration, pending positive outcomes. #IPF #PulmonaryFibrosis #Biopharma #ClinicalResearch #BayesianAnalysis #CHEST2024 #HealthcareInnovation